Testing, Treatment, Care and Support Revised Actions for Phase II.

Slides:



Advertisements
Similar presentations
Nursing Advisor Modernisation Agency
Advertisements

February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
A Health and Wellbeing Board for Leicestershire Cheryl Davenport Programme Director.
16+ Learning Choices Ann Carnachan Head of School Improvement Falkirk Council.
Developing Substance Misuse Education in the Borders.
February Dakar, Senegal
Thursday March SEN developments Jess Haslam.
Establishing a Managed Care Network for Hepatitis C
Hepatitis C Managed Care Network Process of development, strengths and challenges Justin Schofield, Hepatitis C MCN Manager
Hepatitis C Education, Training & Awareness-raising Network Phase II Actions NHS Greater Glasgow and Clyde Hepatitis C Managed Care Network Event 11 June.
Working Together Strategic Review of Community Safety 2009.
THE AFRICA LOCAL GOVERNMENT ACTION FORUM (ALGAF) PHASE IV SESSION V
Morag Ferguson and Susan Shandley Educational Projects Managers
1 Children’s Service budget proposals 2013/14 Formal consultation.
Representing Central Government in the South East Monday, 27 April 2015 Vivien Lines DCSF Safeguarding Adviser VCS Safeguarding Seminar 17 December 2009.
An electronic patient record for CLEFTSiS – the National Managed Clinical Network for Cleft Services in Scotland John Clark, Lead Clinician CLEFTSiS and.
Update: Operational Delivery Networks Denise McLellan Transitional Lead, Networks and Senates, Midlands and East November 2012.
Hepatitis C Action Plan Prevention Working Group Findings and recommendations Norah Palmateer Health Protection Scotland Greater Glasgow & Clyde MCN June.
Disability and special educational needs: local area responsibilities under the Children and Families Act, 2014 Charlie Henry HMI National lead for disability.
Understanding how commissioners work, and the ways in which HITs can influence their decisions Louise Rickitt & Mel Green June 2015.
Hepatitis C Action Plan: Phase II Programme Management Approach.
Developing a National Paediatric Diabetes Plan: What are the key issues for education? Dr. Sheridan Waldron HCP Education Lead for Children and Young people.
HOW GOOD ARE WE AT REDUCING THE RISK? AN AUDIT OF HEPATITIS B VACCINATION IN BABIES BORN TO DRUG USING FAMILIES Josie Murray Specialty Registrar in Public.
Council for Disabled Children May What is Independent Support? A 2-year programme to provide additional support to young people and parents during.
The Tayside Experience The Long Road To Implementation Peter Rice, Consultant Psychiatrist, NHS Tayside Alcohol Problems Service.
SEN and Disability Green Paper Pathfinders March 2012 Update.
Integrated Therapy Service for Children and Young People Frances Rowe, Service Manager – October 2013.
ACJRD 16 th Annual Conference 4 th October  2007: Prevention and Early Intervention Programme, funded by DYCA and The Atlantic Philanthropies;
Needs Assessment: Young People’s Drug and Alcohol Services in Edinburgh City EADP Children, Young People and Families Network Event 7 th March 2012 Joanne.
Support and aspiration: A new approach to special educational needs and disability Ann Gross, DfE 7 November 2011.
Testing, Treatment, Care and Support Draft Actions for Phase II.
Objectives 1. Children will be supported in an integrated way through the establishment of a Start Right Community Wrap- Around Programme in the target.
Educational Solutions for Workforce Development Education to support implementation of the National Delivery Plan for Children and Young People.
National Support Team: Findings from the first 2 years Katrina Stephens Associate Delivery Manager, Alcohol Harm Reduction National Support Team, Department.
1 WERT: WP 5 RG EVANS ASSOCIATES November 2010 Aim To pilot and evaluate the content and context of the course material with target groups To help women.
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
Action Plan Advisory Board Action Plan Governance Board Scottish Government Lead Organisation Representatives Chairs of Lead National Networks Scottish.
1 Women Entrepreneurs in Rural Tourism Evaluation Indicators Bristol, November 2010 RG EVANS ASSOCIATES November 2010.
Commissioning Self Analysis and Planning Exercise activity sheets.
SEN and Disability Green Paper: Update March
Autistic Spectrum Disorder Strategic Action Plan 2008 – 2011: National Update David Poole ASD Regional Support Team Manager 6 th May 2010.
Network Update Cathy Young Managed Care Network Manager 16 th June 2011.
Getting it Right for Every Learner in Renfrewshire: A Partnership Approach for Additional Support Needs (Draft Revised Renfrewshire ASL Act Implementation.
My healthy life Helen Mycock – Mencap Health programme manager.
Proposed Priority Actions By NSF Goals (before group work) By Rose Nalwadda 1 st February 2006.
School Improvement Partnership Programme: Summary of interim findings March 2014.
1 2009/10 DIVISION OF REVENUE BILL Presentation to Select Committee on Finance 24 February 2009.
Preparing for Winter 2011/12 Guidance Overview Stuart Low Planning Manager Scottish Govt NHSScotland Business & Performance Mgt Team.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
Choose Life Evaluation Phase 2. Purpose Phase 2 – Outcome - inform future investment in, and the direction of, Choose Life from 2010 onwards and.
How aspirations can be built and levels of performance can be assured: Learning from the Scottish Action Plan Professor Sharon Hutchinson LJWG LDAPF Conference.
QUALITY INDICATORS FOR HEPATITIS C Michele Hilton Boon Ray Fox, Clare Echlin, Scott Horton, Hepatitis C Project Group.
Presentation By L. M. Baird And Scottish Health Council Research & Public Involvement Knowledge Exchange Event 12 th March 2015.
Sexual Health in South Tyneside Paula Phillips Public Health Strategic Manager.
Alcohol Drugs and Hepatitis C, Brewing up a perfect storm COSLA Haymarket, Edinburgh 24 June 2015 Epidemiological overview Professor David Goldberg, Health.
1 Progress on the sexual health plan Dr John Logan Consultant in Public Health Medicine
Health and Social Care integration Gordon Neill, Senior Manager March 2016.
Developing a national governance framework for health promotion in Scottish hospitals Lorna Smith Senior Health Improvement Programme Officer NHS Health.
Training for organisations participating in Peer Review of Paediatric Diabetes.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
SPECIAL EDUCATIONAL NEEDS & DISABILITY CODE OF PRACTICE 2015 HOW THIS APPLIES TO FURTHER EDUCATION.
SIGN ROCKETS & Implementation Support Ali El-Ghorr Implementation Advisor SHTG/12 June 2009/Paper 02 HSRE_SHTG_Meetings_ _Paper 2_ SIGN Rockets.
Kick Off Meeting Largs, Scotland
9/16/2018 The ACT Government’s commitment to Performance and Accountability – the role of Evaluation Presentation to the Canberra Evaluation Forum Thursday,
Introduction to the training
Blood borne viral hepatitis action in Wales
Regional Oncology Social Work
Strategy
Hepatitis C Testing, Treatment, Care and Support
Presentation transcript:

Testing, Treatment, Care and Support Revised Actions for Phase II

Action 1: Each NHS Board will have, or be affiliated to, a Managed Care Network (MCN) for Hepatitis C; this Network should comprise representatives of all stakeholder groups including those for the prison service, local authority social work, the voluntary sector, addictions/mental health, and people living with and affected by Hepatitis C. The Network should be guided in its practice through the use of “care” guidelines, prepared by the Hepatitis C Action Plan’s Testing, Treatment, Care and Support Working Group and SIGN Guidelines on Hepatitis C. Outcome (Desired): MCNs for all NHS Boards established and accredited. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: MCN accreditation. Timescale: MCNs established by May 2008 (first meeting) and accredited by Funding: Requirement: Hepatitis C MCN Co-ordinators (7 WTE each AfC band 6, July March 2011). 2008/09: £181, /10: £241, /11: £241,562 Total Costs: £664,296

Action 2: NHS Quality Improvement Scotland (QIS) will develop standards for Hepatitis C testing and the treatment, care and social support of persons with Hepatitis C infection. Outcome (Desired): NHS QIS standards developed. Responsibility: Lead Organisation: NHS QIS. Partners:

Performance Indicators: Auditing against the published Standards. Timescale: NHS QIS standards developed by Funding: Requirement: Funding to be sourced separately from NHS QIS Core Budget:

Action 6: Testing, Treatment, Care and Support services within each NHS Board will be developed to increase the numbers of persons undergoing therapy (currently 450/year). Outcome (Desired): 500 treated in 2008/2009, 1,000 in 2009/2010, 1,500 in 2010/2011, and at least 2,000/year thereafter. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: Number of persons offered therapy. Number of persons commenced on antiviral therapy. Proportion of those having received antiviral therapy who achieved a sustained viral response Timescale: Targets for as indicated. Funding: Requirement: Increased provision of testing, treatment, care and support (see attached spreadsheets for detail on costs). 2008/09: £2,700, /10: £9,500, /11: £15, Total costs:£27,700,000

Action 7: Service Level Agreements/Memorandums of Understanding, between NHS Boards and the Scottish Prison Service (SPS), to promote the management of Hepatitis C treated persons in medium and long-stay prisons, should be developed taking into account the SPS BBV strategy. Outcome (Desired): The establishment of SLAs/MOUs between SPS and NHS Boards. Approximately 10% of all Hepatitis C treated persons in Scotland (as above) should be prison inmates. Responsibility: Lead Organisation: SPS. Partners:

Performance Indicators: Number of persons offered therapy (prisons only). Number of persons commenced on antiviral therapy (prisons only). Proportion of those having received antiviral therapy who achieved a sustained viral response (prisons only). Timescale: SLAs/MoUs by Nov Targets for as indicated above. Funding: Requirement: Increased provision of testing, treatment, care & support included above (see Action 6).

Action 8: For each NHS Board a formal plan, indicating how it has integrated/will integrate appropriate elements of Hepatitis C specialist treatment and care services into those for addiction/mental health including both primary and secondary care, will be developed and implemented Outcome (Desired): Development and implementation of plan. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: Through MCN accreditation. Timescale: Plan developed by March 2009 with implementation thereafter. Funding: Requirement: Funding for MCN Co-ordination included above (see Action 1).

Action 9: Each Local Authority will identify a Strategic and Operational Lead for Hepatitis C infection. Outcome (Desired): Local Authority Leads established. Responsibility: Lead Organisation: Local Authorities. Partners:

Performance Indicators: Local Authority Lead identified. Timescale: Leads identified by July Funding: Requirement: Funding for increased provision of care and support included above (see Action 6).

Action 10: NHS Boards will work in partnership with General Practitioners (GPs) to develop and implement a plan, incorporating innovative approaches, to improve Hepatitis C testing and referral activities. Outcome (Desired): A plan to increase testing, diagnosis and referral by GPs. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: Numbers of persons Hepatitis C tested, Hepatitis C diagnosed and referred to specialist care services by GPs. Timescale: Development of plan by March 2009 with implementation thereafter. Funding: Requirement: Funding for MCN Co-ordination included above (see Action 1) and funding for increased provision of testing included above (see Action 6).

Action 12: A programme of work to evaluate different approaches to Hepatitis C testing/ Hepatitis C test sampling (e.g. near patient testing/use of saliva and dried blood spots) will be undertaken. Outcome (Desired): Programme of Hepatitis C testing/sampling work undertaken. Responsibility: Lead Organisation: Hepatitis C Specialist Laboratories. Partners:

Performance Indicators: Timescale: Funding: Requirement: Sheila Cameron and Sheila Burns to provide costed proposal. Year 1:£200,000 Year 2: £200,000 Year 3: £0 Total costs:£400,000

Prevention Revised Actions for Phase II

Action 13: Each NHS Board will have, or be affiliated to, a Network covering the prevention of Hepatitis C and comprising representatives of all stakeholder sectors. Each NHS Board will identify a Hepatitis C Prevention Lead. Guidance regarding Network membership and Terms of Reference for the Hepatitis C component will be established. Outcome (Desired): Hepatitis C requirements for the Network established and Prevention Leads (Hepatitis C) appointed. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: Audit against the guidelines (Action 14). Timescale: Hepatitis C requirements for Prevention Network agreed and implemented by September Prevention Leads appointed by May Funding: Requirement: National Hepatitis C Prevention Network Co-ordinator (1 AfC band 7, July 2008-March 2011). 2008/09: £30, /10: £41, /11: £41,207 Total costs:£

Action 14: Guidelines for services providing injection equipment to IDUs will be developed. Outcome (Desired): Guidelines developed. Responsibility: Lead Organisation: Scottish Government. Partners:

Performance Indicators: Audit against the Guidelines. Timescale: Interim Guidelines developed by November Final Guidelines by July Funding: Requirement: Production, printing and dissemination of Guidelines. 2008/09: £100, /10: £02010/11: £0 Total costs:£100,000

Action 15: Services providing injection equipment will be improved in accordance with Guidelines (Action 14). Outcome (Desired): Increased uptake of injection equipment. Reduction in reported sharing of injecting equipment among IDUs. Reduction in the incidence of Hepatitis C infection among IDUs. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: Proportion of injection episodes undertaken with sterile injecting equipment (needles and syringes and other injecting paraphernalia). Proportion of IDUs sharing injecting equipment during a specified period. Hepatitis C prevalence/incidence among recent onset injectors. Baseline data will be available in 2008 and, thereafter, targets will be set. Timescale: Each Network to provide a plan of action by March Implementation in Funding: Requirement: Increased provision of injecting equipment (funding in 2008/2009 based on NHS Boards report of spending £565,023 in 2007/2008 on improving services to prevent Hepatitis C; funding for 2009/2010 and 2010/2011 based on Scottish Government allocation in spending review). 2008/09: £600, /10: £3,000, /11: £3,000,000 Total costs:£6,600,000

Action 17: A research initiative to provide injection equipment through vending machines will be evaluated. Outcome (Desired): Implementation and evaluation of research initiative. Responsibility: Lead Organisation: HPS. Partners:

Performance Indicators: Measures of use and acceptability. Timescale: Design 2008/2009. Evaluation 2009/2010. Report Funding: Requirement: Funding to be sourced from that allocated to Action 15.

Action 18: An in-prison needle/syringe exchange initiative will be piloted as one of a range of harm reduction measures to reduce the transmission of Hepatitis C. Outcome (Desired): The implementation and external evaluation of the initiative. Responsibility: Lead Organisation: SPS Partners:

Performance Indicators: Measures of use and acceptability. Timescale: The implementation and external evaluation of the initiative by Funding: Requirement: Evaluation of an in-prison pilot needle exchange initiative. 2008/09: £50, /10: £100, /11: £50,000 Total costs:£200,000

Education, Training and Awareness-raising Revised Actions for Phase II

Action 3: A national Hepatitis C Learning and Workforce Development Framework will be developed. Outcome (Desired): A knowledgeable, skilled and confident Hepatitis C workforce. Responsibility: Lead Organisation: NHS Education for Scotland Partners:

Performance Indicators: MCN accreditation (see Action 4). Timescale: Framework to be developed and published by December 2008, implemented throughout 2009/2011. Funding: Requirement: National Hepatitis C Workforce Development Co-ordinator (1 WTE each AfC band 7, April 2008-March 2011). 2008/09: £41, /10: £41, /11: £41,207 Total costs:£123,621

Action 4: NHS Boards, working with their partners, such as local government, the voluntary sector and the Scottish Prison Service (SPS), will review the learning and development needs of the Hepatitis C workforce and implement a co- ordinated approach to Hepatitis C workforce development consistent with the national Hepatitis C Learning and Workforce Development Framework. NHS Boards will appoint an Hepatitis C workforce development co-ordinator to support the implementation of a co-ordinated local approach to Hepatitis C workforce development. Outcome (Desired): A knowledgeable, skilled and confident Hepatitis C workforce. A co-ordinated local approach to Hepatitis C workforce development. Responsibility: Lead Organisation: NHS Boards. Partners:

Performance Indicators: MCN accreditation (Staff Training element) and Review against NHS QIS Standards. Timescale: NHS Board Workforce Development Leads to be identified by September NHS Boards to assess the learning and development needs of their HCV workforce by December NHS Boards to implement a co-ordinated approach to Hepatitis C workforce development throughout 2009/11. Funding: Requirement: Local Hepatitis C Workforce Development Co-ordinators (7 AfC band 6, Dec March 2011). Year 1:£80,521 Year 2: £241,562 Year 3: £241,562 Total costs:£563,645

Action 5: Awareness-raising campaigns and communications activity will continue to be developed to meet the information and educations needs of a range of professional audiences. Outcome (Desired): Increased awareness and knowledge of Hepatitis C and its management among professional audiences. Responsibility: Lead Organisation: Scottish Government. Partners:

Performance Indicators: Awareness of communications activity and messages tracked by national tracking surveys/activity. Timescale: Communications activities to be undertaken throughout Funding: Requirement: Funding to be sourced separately from the Scottish Government Core Communications Budget.

Action 11: An awareness campaign, to promote Hepatitis C testing among those at risk of being infected will be implemented and evaluated. Outcome (Desired): Improved awareness levels of Hepatitis C among target audiences. Increased numbers presenting for a Hepatitis C test. Responsibility: Lead Organisation: Scottish Government. Partners:

Performance Indicators: Awareness of communications activities and messages tracked by national tracking surveys/activity. Numbers of persons Hepatitis C tested. Timescale: Campaign to be implemented by September 2009 with evaluation by March Funding: Requirement: Funding to be sourced separately from the Scottish Government Core Communications Budget.

Action 16: Educational interventions aimed at vulnerable individuals, IDUs and those at risk of starting to inject will be designed and undertaken to highlight how Hepatitis C transmission can be prevented. These include: prevention programmes, approaches to family support, peer education and other relevant interventions. Outcome (Desired): Increased awareness of Hepatitis C among IDUs and those at risk of injecting. Responsibility: Lead Organisation: NHS Health Scotland. Partners:

Performance Indicator: Proportion of injection episodes undertaken with sterile injecting equipment (needles and syringes and other injecting paraphernalia). Proportion of IDUs sharing injecting equipment during a specified period. Hepatitis C prevalence/incidence among recent onset injectors. Baseline data will be available in 2008 and, thereafter, targets will be set. Timescale: A range of interventions to be implemented throughout Funding: Requirement: Hepatitis C Education and Awareness-raising Co-ordinator (1 AfC band 7, July 2008-March 2011). 2008/09: £30, /10: £41, /11: £41,207 Total costs: £113,319 Local implementation of NHS Boards educational interventions. 2008/09: £0 2009/10: £500, /11: £500,000 Total costs: £1,000,000

Action 19: Blood Borne Viruses (including Hepatitis C) Guidance and educational support materials will be developed and disseminated to raise awareness of the health and social impact of Blood Borne Viruses and support the education of young people in primary, secondary and further education settings and settings supporting vulnerable young people. Outcome (Desired): Increased awareness and knowledge of BBV (including Hepatitis C) among young people in schools, further education settings and settings supporting vulnerable young people. Increased confidence of key staff to support BBV related education. Uptake of educational materials. Responsibility: Lead Organisation: Learning and Teaching Scotland. Partners:

Performance Indicator: Levels of BBV (including Hepatitis C) education in schools, further education settings and settings supporting vulnerable young people. Knowledge of BBV (including Hepatitis C) among young people and young adults. Timescale: Educational support materials to be published by June Funding: Requirement: Production, piloting, printing and dissemination of materials. 2008/09: £70, /10: £30, /11: £0 Total costs: £100,000

Monitoring and Surveillance Actions for Phase II

Action 20 The further development of the National Hepatitis C Clinical Database, including the establishment of a Generic Clinical System for Hepatitis C. Outcome (desired): The establishment of a Generic Clinical System for Hepatitis C, reporting annually on the performance indicators for Actions 6-7. Responsibility: Lead Organisation: HPS Partners: Hepatitis C Clinical Database Monitoring Committee, NHS Boards, (others to include)

Performance Indicator: (See Outcome) Timescale: Establishment of a Generic Clinical System for Hepatitis C by December Progress and available NHS Board data published in Annual Report by May 2009, and all NHS Board data published in Annual Report by May Funding: Requirement: Continued development of the National Hepatitis C Clinical Database (Includes funding for: data-entry at HCV Clinics, Generic Clinical System Development, National HCV Clinical Database Manager, Epidemiologist/Information Analyst and Travel). 2008/09: £182, /10: £347, /11: £202,000 Total costs: £731,000

Action 21 Development of a surveillance system to monitor Hepatitis C testing practice in Scotland. Outcome (desired): The establishment of a Hepatitis C Test Database, reporting annually on the performance indicators for Actions 10 and 11. Responsibility: Lead Organisation: HPS Partners: BBV Specialist Laboratories, NHS Boards, (others to include)

Performance Indicator: (See Outcome) Timescale: Establishment of a Hepatitis C Test Database relating to all NHS Boards by December Progress and available NHS Board data published in Annual Report by May 2009, and all NHS Board data published in Annual Report by May Funding: Requirement: Development of a Hepatitis C Test Database (Includes funding for: Epidemiologist; IT Support; Travel) 2008/09: £79, /10: £79, /10: £79,000 Total costs: £237,000

Action 22 Development of a surveillance system to monitor the provision of injecting equipment in Scotland. Outcome (desired) The establishment of a Database on Injecting Equipment Provision reporting annually on the performance indicator for Action 14. Responsibility: Lead Organisation: ISD Partners: HPS, NHS Boards, ADATs, (others to include)

Performance Indicator: (see Outcome) Timescale: Establishment of a Database on Injection Equipment Provision by June Data published annually in relevant reports such as Drug Misuse Statistics Scotland by December Funding: Requirement: Development of a Database on Injection Equipment Provision. 2008/09: £150, /10: £150, /11: £150,000 Total costs: £450,000

Action 23 Annual surveys of Hepatitis C prevalence and incidence among injecting drug users across Scotland will be undertaken. Outcome (desired): The implementation of surveys, reporting annually on the performance indicators for Actions 15 and 16. Responsibility: Lead Organisation: HPS Partners: University of the West of Scotland, Hepatitis C Specialist Laboratories, NHS Boards, (others to include)

Performance Indicator: (see Outcome) Timescale: Surveys undertaken annually and data published in Annual Report by May Funding: Requirement: Annual surveys of Hepatitis C prevalence/incidence and associated behaviours/service use among IDUs in Scotland. 2008/09: £306, /10: £450, /11: £417,000 Total costs: £1,173,000

Action 24 A survey of Hepatitis C prevalence among prisoners in Scotland will be undertaken. Outcome (desired): The implementation of, and report on, the survey. Responsibility: Lead Organisation: HPS Partners: SPS, (others to include)

Performance Indicator: (see Outcome) Timescale: Survey undertaken and data published in report by March Funding: Requirement: Survey of Hepatitis C prevalence among Prisoners in Scotland. 2008/09: £42, /10: £252, /11: £95,000 Total costs: £389,000

Action 25 Surveys to estimate the prevalence of Hepatitis C among i) people in Scotland who have lived in Pakistan and ii) children in Scotland will be undertaken. Outcome (desired): The implementation of, and report on, surveys. Responsibility: Lead Organisation: HPS Partners: GG & C NHS Board, University of Glasgow Dental School, (others to include)

Performance Indicator: (see Outcome) Timescale: Surveys undertaken and data published in reports by March Funding: Requirement: Surveys of Hepatitis C prevalence among i) people in Scotland who have lived in Pakistan and ii) children in Scotland. 2008/09: £50, /10: £150, /11: £50,000 Total costs: £250,000

Co-ordination (governance, communications and project management) Actions for Phase II

Action General The establishment of new groups, the modification of existing groups, the implementation of a new accountability and reporting structure, the further development of communication arrangements and the project management approach.

Action 26 Establishment of new groups, including: (i) A National Managed Care Network Leads Group (see Action 1), (ii) A National Prevention Leads Group (see Action 13), and (iii) An NGOs/Voluntary Sector Group. Outcome (desired): Reshaped governance arrangements Responsibility: Lead Organisation: HPS Partners: Performance Indicator: Delivery of Actions within agreed costs and timescales.Timescale: Implemented by June 2008.

Action 27 Review and modification of existing Groups (including Membership and Terms of Reference): (i) The Action Plan Co-ordinating Group, (ii) The Hepatitis C Executive Leads Group, (iii) The Action Plan Project (now Programme) Implementation Group, (iv) The Education, Training and Awareness-raising Group. Outcome (desired): Reshaped governance arrangements Responsibility: Lead Organisation: HPS Partners: Performance Indicator: Delivery of Actions within agreed costs and timescales. Timescale: Implemented by June 2008.

Action 28 The Implementation and development of a new accountability and reporting structure. Outcome (desired): Reshaped governance arrangements Responsibility: Lead Organisation: HPS Partners: Performance Indicator: Delivery of all Actions within agreed costs and timescales. Timescale: Implemented by June 2008.

Action 29 Actions to enable Hepatitis C Stakeholders to keep abreast of Action Plan progress and outputs, and to provide feedback on these; including: (i) The development of the existing Hepatitis C Scotland website, including a stakeholder forum, (ii) The production of a Scottish Hepatitis C Action Plan Annual Report, (iii) A Scotland contribution to a UK Annual Report on Hepatitis C (with HPA), and (iv) The holding of an annual Stakeholder meeting. Outcome (desired): Further development of the Project Communications Plan. Responsibility: Lead Organisation: HPS Partners: Performance Indicator: Delivery of all Actions within agreed costs and timescales. Timescale: Preliminary website development May 2008, full development by Dec Annual Report by May UK Annual Report by Nov Annual Stakeholder meeting in May 2009.

Action 30 Further development of the programme management approach, including: (i) The establishment of a new project management team, and (ii) The development of a project management plan. Outcome (desired): Further development of the Project Plan. Responsibility: Lead Organisation: HPS Partners: Performance Indicator: Delivery of all Actions within agreed costs and timescales. Timescale: Implemented by June 2008.

Funding RequirementTotal Costs ( ) a) Meetings including an annual stakeholder conference, APCG, Exec Lead, MCN Lead and Prevention Lead meetings £49,500 b) Admin Support (2 Band 4)£140,072 c) Hepatitis C Action Plan Communications & Website Manager (1 Band 7) £123,621 d) IT/Web/Graphics Technical Support (0.4 AfC Band 5 £33,547 e) Annual Report Production£15,000 f) Hepatitis C Action Plan Portfolio Manager (0.4 AfC Band 8a) £60,979 g) Hepatitis C Action Plan Project Manager (1 AfC Band 7) £123,621 h) Computing, Licences and Recruitment Costs£80,000 i) HCV Executive Lead Support Officers (7 AfC Band 6, April 2008 – March 2011 £724,686 a)– h) : HPS i) : NHS Boards